<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808768</url>
  </required_header>
  <id_info>
    <org_study_id>ID IIT- 000373</org_study_id>
    <nct_id>NCT01808768</nct_id>
  </id_info>
  <brief_title>Ocular Allergy Treatment Practical Impact Trial</brief_title>
  <acronym>(OAT-PIT)</acronym>
  <official_title>To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Starx Research Center, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Starx Research Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or
      specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no
      treatment) versus alcaftadine(Lastacaft™)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life- Eye Allergy Patient Impact Questionnaire</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index Pollen Count correlation of symptoms</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Alcaftadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcaftadine</intervention_name>
    <description>Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.</description>
    <arm_group_label>Alcaftadine</arm_group_label>
    <other_name>Lastacaft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients age 18 and older with a history of seasonal or perennial forms of allergic
             conjunctivitis and skin test positive reactivity to seasonal aeroallergens

          2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.

          3. have allergic ocular symptoms for the past week for which they are either treating
             with ophthalmic agents or have had no treatment.

          4. Are willing/able to follow instructions from the study investigator and his/her study
             staff.

          5. Have signed infromed consent approved by Institutional Review Board or Independent
             Ethics Committee.

        Exclusion Criteria:

          1. Active ocular infection;

          2. History of retinal detachment, diabetic neuropathy, or any progressive retinal
             disease;

          3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled
             during the study.

          4. History of unstable, or uncontrolled disease of any nature.

          5. Pregnancy or lactation;

          6. Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayesh Kanuga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Starx Research Center, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jayesh Kanuga, MD</last_name>
    <phone>732-906-1747</phone>
    <email>jkanuga@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erika Julca, LPN,CRC</last_name>
    <phone>732-906-1747</phone>
    <email>ejulca1@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>STARx Research Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Julca, lpn,crc</last_name>
      <phone>732-906-1747</phone>
      <email>ejulca1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>June Pepe, lpn, ccrc</last_name>
      <phone>973-912-9817</phone>
      <email>pepejune@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jayesh Kanuga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ligaya Centeno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruby Reyes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonard Bielory, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>STARx</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Bielory, MD</last_name>
      <phone>973-912-9817</phone>
      <email>DrLBielory@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonard Bielory, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Starx Research Center, LLC</investigator_affiliation>
    <investigator_full_name>Jayesh G. Kanuga, M.D.</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcaftadine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 13, 2013</submitted>
    <returned>February 4, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

